Financial Review: Arvinas (NASDAQ:ARVN) vs. Heyu Biological Technology (OTCMKTS:HYBT)

Arvinas (NASDAQ:ARVN) and Heyu Biological Technology (OTCMKTS:HYBT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Volatility and Risk

Arvinas has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Heyu Biological Technology has a beta of -17.74, suggesting that its share price is 1,874% less volatile than the S&P 500.

Valuation & Earnings

This table compares Arvinas and Heyu Biological Technology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60 million	2.26	-$80.80 million	$0.10	91.80
Heyu Biological Technology	$80,000.00	129.19	-$270,000.00	N/A	N/A

Heyu Biological Technology has lower revenue, but higher earnings than Arvinas.

Insider and Institutional Ownership

95.2% of Arvinas shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 89.2% of Heyu Biological Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Arvinas and Heyu Biological Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Heyu Biological Technology	-453.55%	-6.43%	-4.43%

Analyst Recommendations

This is a summary of current recommendations and price targets for Arvinas and Heyu Biological Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2	4	5	0	2.27
Heyu Biological Technology	0	0	0	0	0.00

Arvinas currently has a consensus price target of $14.17, indicating a potential upside of 54.32%. Given Arvinas’ stronger consensus rating and higher probable upside, research analysts clearly believe Arvinas is more favorable than Heyu Biological Technology.

Summary

Arvinas beats Heyu Biological Technology on 9 of the 12 factors compared between the two stocks.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.